Clinical Trial Update: A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation [Phase 3]

View source ↗

Summary

Phase 3 randomized trial investigating HIPEC in recurrent ovarian cancer patients with HRR gene mutations; status not yet determined.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Hyperthermic intraperitoneal chemotherapy (HIPEC)

Snippet

Sponsor: CAI Hongbing | Conditions: Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Status: UNKNOWN